In our previous studies, we demonstrated that HDAC inhibitors effectively reduce the viability of melanoma cells and may render this type of cancer more susceptible to the cytotoxic effects of DNA-damaging agents, such as dacarbazine [26]. The gene discussed is HDAC9; the disease is cancer.